Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — FY2014 Earnings Presentation
39 slides from Cytosorbents's earnings presentation, Apr 8, 2015
Slide 1: An Emerging Leader in Critical Care Immunotherapy: Year 2014 Earnings Call
Cyto Sorbents Corporation NASDAQ CM: CTSO An Emerging Leader in Critical Care Immunotherapy Year 2014 Earnings Call March 31, 2015
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents, Inc (now known as CytoSorbents Medical Inc) and CytoSorbents Europe GmbH that are not historical facts are forward - looking statements and are subject to risks and u
Slide 3: Well-Positioned as a Leader in Critical Care Immunotherapy
3 Cyto Sorbents is Well - Positioned as A Leader in Critical Care Immunotherapy Leading the Prevention or Treatment of Life - Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb ® Blood Purification
Slide 4: 2014: A Strong Year of Growth
4 2014: A Strong Year of Growth
Slide 5: Achieved 2014 CytoSorb Sales of $3.1M
5 Driven by a growing combination of Direct Sales, Independent Distributor Sales, and Strategic Partner Sales WMC Intensiv Med LLC Achieved 2014 CytoSorb Sales of $3.1M
Slide 6: 2nd CytoSorb Germany User's Meeting
6 2 nd CytoSorb Germany User’s Meeting
Slide 7: 1st International CytoSorb User's Meeting
7 1 st International CytoSorb User’s Meeting
Slide 8: ISICEM 2015
ISICEM 2015 TI
Slide 9: More Published Case Reports & Studies
9 More Published Case Reports & Studies
Slide 10: Launched International CytoSorb Registry
10 Launched International CytoSorb Registry • The home of 40+ planned investigator initiated studies with many already enrolling
Slide 11: Launched New CytoSorb Website
11 Launched New CytoSorb Website www.cytosorb.com
Slide 12: Partnered with Global Leaders
12 Partnered with Global Leaders
Slide 13: Expansion of Biocon Partnership
13 Expansion of Biocon Partnership • According to Biocon , hundreds of patients have benefited from CytoSorb ® therapy and orders continue to increase • Expanded agreement beyond sepsis to all critical care applications and cardiac surgery with a focus on the systemic inflammatory response syndrome
Slide 14: Fresenius Medical Care
14 Fresenius Medical Care • Entered into a 6 country partnership with Fresenius, the largest dialysis company in the world for exclusive distribution of CytoSorb® in critical care in France, Sweden, Norway, Finland, Denmark and Poland • Leveraging Fresenius’ #1 or #2 position in critical care in the
Slide 15: Cardiac Surgery Initial Partnership
15 Cardiac Surgery Initial Partnership • Entered into an initial partnership with a top - four global medical device company in cardiac surgery to use CytoSorb ® intra - operatively during cardiac surgery in France • Initial evaluation phase expected to be complete in Q2 2015 • Following a successfu
Slide 16: Focus on Generating Clinical Data
16 Focus on Generating Clinical Data
Slide 17: FDA Approval of IDE for REFRESH Study
17 FDA Approval of IDE for REFRESH Study • REFRESH ( R eduction in FRE e H emoglobin) Trial is a 20 - patient multi - center feasibility study evaluating the safety of CytoSorb use intra - operatively in a bypass circuit in a heart - lung machine during complex cardiac surgery as a means of reducing
Slide 18: Infrastructure to Drive Clinical Data
18 United States European Union Director of European Scientific Affairs 50+ Investigator Initiated Studies EU Sepsis Studies Pivotal Trial Cardiac Surgery European Registry US Air Force Funded Trauma Pilot Case Reports Germany Dosing Study Medical Director SVP of Clinical Development Trauma Advisory
Slide 19: Increased Investor Awareness
19 Increased Investor Awareness
Slide 20: NASDAQ Capital Market Listed
20 NASDAQ Capital Market Listed CytoSorbents (CTSO) Up - listed to NASDAQ in December 2014 • Average daily trading volume: 200K shares ($3M daily trading value) vs 30,000 prior to up - listing
Slide 21: #11 on Forbes Best Performing Stocks of 2014
21 #11 on Forbes Best Performing Stocks of 2014 CytoSorbents Achieved Strong Stock Performance in 2014 comparing favorably to peers
Slide 22: Continued Positive Analyst Coverage and Investor Outreach
22 Continued Positive Analyst Coverage and Investor Outreach
Slide 23: Increased Media Coverage
Increased Media Coverage aaa | +MASS : DEVICE MEDICAL DEVICE DAILY” craemameaa ncsntenae ee rocpacapest reenter nt one went romeo nemo me arene se epost ee cient tensa rt ata Rae secomplan i a fargry pavents renee caida evaporite ANS "aie Russo 09a FDANEWS itviog Global Comic res OE for Cpt ‘Sir ee
Slide 24: Operating and Financial Highlights
24 Operating and Financial Highlights
Slide 25: 2014 Comparative Revenue Results
25 2014 Comparative Revenue Results • Achieved record CytoSorb® annual sales of $3.1 M, a 282% increase over $822K in 2013. • Grant and other income declined by 38% as a result of the conclusion of several significant grants. • Gross margin on product sales in 2014 were approximately 63%, as compare
Slide 26: Rapidly-Growing Year-Over-Year Product Sales
26 Rapidly - Growing Year - Over - Year Product Sales $13,679 $87,960 $176,098 $127,969 $203,561 $314,159 $570,000 $0 $100,000 $200,000 $300,000 $400,000 $500,000 $600,000 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 EST CytoSorb ® Product Sales Quarter over quarter growth rate has averag
Slide 27: Quarterly Product Sales
27 Quarterly Product Sales $13,679 $87,960 $176,098 $127,969 $203,561 $314,159 $569,243 $663,233 $1,031,761 $871,150 $0 $200,000 $400,000 $600,000 $800,000 $1,000,000 $1,200,000 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 CytoSorb® Product Sales • Q4 2014 Product
Slide 28: Product Sales Trends Remain Strong
28 Product Sales Trends Remain Strong $151,574 $310,779 $405,706 $595,588 $821,787 $1,214,932 $1,750,196 $2,578,396 $3,135,387 $- $500,000 $1,000,000 $1,500,000 $2,000,000 $2,500,000 $3,000,000 $3,500,000 $4,000,000 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Trailing Twe
Slide 29: Balance Sheet and Cap Table
29 Balance Sheet and Cap Table Consolidated Balance Sheet Data: 12/31/2014 Cash and Short-Term Investments 5,549,827$ * Total Assets 8,468,625$ Total Debt -$ Total Shareholder's Equity 3,963,183$ * * Does not relfect an additional $10.3M financing completed in January 2015. Common stock outstanding
Slide 30: Outlook for 2015
Outlook for 2015 main C¥tOSorbents orhing Wo Save Lives Trough Blood Puriteation
Slide 31: $20 Billion Opportunity in Critical Care
31 $20 Billion Opportunity in Critical Care Millions of people are admitted to the intensive care unit in hospitals in the U.S. and the European Union each year with deadly inflammatory conditions • In these conditions, massive inflammation driven by a “cytokine storm” causes cell death and organ fa
Slide 32: CytoSorb Removes the Fuel to the Fire
32 Cyto Sorb ® Removes the Fuel to the Fire • CytoSorb ® represents a powerful immunotherapy to control inflammation • Approved in the European Union as the only specifically approved cytokine filter • Clinically proven to remove key cytokines in the blood of critically - ill patients • Approved for
Slide 33: Goal: To Prevent or Treat Organ Failure
33 Goal: To Prevent or Treat Organ Failure Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical The Potential to Revolutionize Critical Care Medicine Improve Patient Outcome and Survival Decrease Costs Of ICU and Patient Care
Slide 34: CytoSorbents Has Tremendous Potential
34 Cyto Sorb ® may help revolutionize critical care medicine, saving lives, and reducing costs • Massive untapped $20 billion unmet, medical need in critical care • CytoSorb® sales are generating significant growth with attractive 65% gross margins • Continued geographic expansion throughout the wor
Slide 35: Near Term Challenges
Near Term Challenges main C¥tOSorbents orhing Wo Save Lives Trough Blood Puriteation
Slide 36: Sales Infrastructure Targets For 2014
36 Sales Infrastructure Targets For 2014 Direct Sales Germany Austria Switzerland Direct Sales 5 Distributors (UK, Ireland, Netherlands, Turkey, Russia) 4 sales reps Distributor/Partner Support Rep Targets for 2014 2013 Distributors Partners Distributors Partners Biocon (India) Germany Austria Switz
Slide 37: Restructuring Targets For 2015
37 Restructuring Targets For 2015 Direct Sales Germany ----------- Austria Switzerland Direct Sales 8 Distributors 4 sales reps International Sales Director + Export Business Manager Targets for 2015 Q1 2015 Distributors Partners Distributors Partners Biocon Fresenius Global Cardiac Surgery Co. Germ
Slide 38: Q1 2015 Revenue Guidance
38 Q1 2015 Revenue Guidance • In general, our product sales are too dependent on the timing and size of orders and cannot yet be accurately predicted • We have given guidance, however, when data from the full quarter is known • Expect that Q1 2015 CytoSorb product revenue will be in the range of $70
Slide 39: Q&A Session
39 Phillip P. Chan, MD, PhD - CEO 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 pchan@cytosorbents.com Cyto Sorbents Corporation NASDAQ CM: CTSO An Emerging Leader in Critical Care Immunotherapy Q&A Session